Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design

Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design

Bibliographic Details
Main Authors:	Singh Ramendra K, Singh Udaya
Format:	Article
Language:	English
Published:	BMC 2011-10-01
Series:	Retrovirology

Similar Items

The rational design and synthesis of novel HIV non-nucleoside reverse transcriptase inhibitors
by: Muller, Ronel
Published: (2013)

Intracellular phosphorylation of nucleoside reverse transcriptase inhibitors
by: Sales, Sean Douglas
Published: (2000)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
by: Meytal Galilee, et al.
Published: (2018-01-01)

Molecular dynamics simulations and docking of non-nucleoside reverse transcriptase inhibitors (NNRTIs): a possible approach to personalized HIV treatment
by: Roessler Florian D, et al.
Published: (2012-05-01)

The design and synthesis of novel HIV-1 non-nucleoside reverse transcriptase inhibitors
by: Pribut, Nicole
Published: (2015)

Designing Novel Hydrazinecarbothioamides as Potential HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Hong Yin, et al.
Published: (2017-10-01)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
by: Lewi Paul, et al.
Published: (2011-10-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
by: Maryam A. Jordaan, et al.
Published: (2020-08-01)

Molecular modeling studies of HIV-1 non-nucleoside reverse transcriptase inhibitors using 3D-QSAR, virtual screening, and docking simulations
by: Tong Jian-Bo, et al.
Published: (2019-01-01)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
by: Pei-Ying Wu, et al.
Published: (2017-01-01)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
by: Anthi Petrou, et al.
Published: (2019-10-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

Kinetic analysis of HIV-1 reverse transcriptase in the presence of non-nucleoside inhibitors
by: Wang, Louise Zhiying
Published: (2008)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020-06-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)

Exploring QSAR of Non-Nucleoside Reverse Transcriptase Inhibitors by Neural Networks: TIBO Derivatives
by: Driss Cherqaoui, et al.
Published: (2004-01-01)

Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review
by: Olga Tarasova, et al.
Published: (2018-05-01)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
by: Aleksandra Dąbrowska, et al.
Published: (2018-10-01)

Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations
by: Van Houtte Margriet, et al.
Published: (2011-10-01)

Exploring QSAR of non-nucleoside reverse transcriptase inhibitors by artificial neural networks: HEPT derivatives
by: Mohamed Zahouily, et al.
Published: (2007-09-01)

3D QSAR Studies of DAMNI Analogs as Possible Non-nucleoside Reverse Transcriptase Inhibitors
by: S. Ganguly, et al.
Published: (2008-01-01)

Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition.
by: R Brad Jones, et al.
Published: (2008-01-01)

Mitochondrial toxicity of nucleoside reverse transcriptase inhibitors in a rat phaeochromocytoma cell line
by: Clarke, Anna B.
Published: (2006)

Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
by: Bienczak, Andrzej Marek
Published: (2017)

Modeling of cytotoxicity on some non- nucleoside reverse transcriptase inhibitors of HIV-1: role of physicochemical parameters
by: B.K. Tiwari, et al.
Published: (2006-02-01)

Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
by: Jean-Guy Baril, et al.
Published: (2003-01-01)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
by: Mastan SK, et al.
Published: (2009-10-01)

Introducing Catastrophe-QSAR. Application on Modeling Molecular Mechanisms of Pyridinone Derivative-Type HIV Non-Nucleoside Reverse Transcriptase Inhibitors
by: Marius Lazea, et al.
Published: (2011-12-01)

On the synthetic way to novel peri-annelated imidazo[1,5]benzo-diazepinones as the potent non-nucleoside reverse transcriptase inhibitors
by: Benedikta D. Puodziunaite, et al.
Published: (2000-09-01)

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection
by: Hanh Thi Pham, et al.
Published: (2020-03-01)

Identification of a novel sulfonamide non-nucleoside reverse transcriptase inhibitor by a phenotypic HIV-1 full replication assay.
by: Tae-Hee Kim, et al.
Published: (2013-01-01)

Design and Synthesis of Novel Sultams: A Family of Non-nucleoside Reverse Transcriptase Inhibitors and Modeling Studies of a Rhodium Catalyst
by: Kafri, Riyam
Published: (2007)

Synthesis and biological evaluation of novel guanine-containing compounds as potential HIV-1 non-nucleoside reverse transcriptase or integrase inhibitors
by: Adebambo, Kassim Folorunsho
Published: (2010)

Molecular Docking Studies of Marine Diterpenes as Inhibitors of Wild-Type and Mutants HIV-1 Reverse Transcriptase
by: Alessandra M. T. de Souza, et al.
Published: (2013-10-01)

Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_thu763kqmcio1sskgsc1t7sn8u